Isabella Schmitt of Proxima Clinical Research Named A Woman to Watch Honoree of Houston Business Journal 2021 Women Who Mean BusinessView All articles
Houston, Oct 22, 2021― Proxima Clinical Research (“Proxima CRO”), a contract research organization (CRO) based out of the Texas Medical Center in Houston, is honored and excited to announce today that Isabella Schmitt, RAC, Director of Regulatory Affairs and all around superstar of the organization has been honored by the Houston Business Journal as one of the prestigious 2021 “Women Who Mean Business.”
Isabella opened up in her interview for this achievement sharing how she starts her successful day (her answer may suprise you) - "It’d be great to say that I am one of those people who wakes up at 4 a.m. to go for a 5-mile run, do yoga, meditate and read the newspaper all before having an ounce of caffeine. But I am not a morning person by any stretch of the imagination, so my day starts with coffee."
Continue reading the rest of Isabella's interview here.
Houston Business Journal started the Women Who Mean Business Awards to recognize the most influential women in business within the Greater Houston area. The awards program recognizes women in leadership roles that have demonstrated excellence in their careers and community. The awards honor women across 11 industry categories plus the Woman to Watch category. The criteria for selection includes career achievement, contribution to company and city success, community involvement and leadership.
About Proxima Clinical Research
Proxima CRO provides the best regulatory and clinical research expertise to life sciences companies regardless of size or stage. With headquarters in the Texas Medical Center(TMC), the largest medical center in the world, Proxima CRO brings its expertise to hundreds of emerging medical device, pharmaceutical, biotechnology, and diagnostic companies in 17 countries across five continents to further advance the $130 billion market. Launched in November 2017, Proxima CRO is a registered Delaware C Corporation.